SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Encore Capital Group entered into a material definitive agreement on May 22, 2026, issuing $750 million in senior secured notes due 2032 with subsidiary guarantees and asset collateral, materially affecting the company's capital structure and financial obligations.
View raw filing on EDGAR →This Item 5.07 disclosure reports the results of Northern Oil & Gas's Annual Meeting of Stockholders held on May 21, 2026, including voting outcomes for three proposals: election of seven directors, ratification of Deloitte & Touche LLP as independent auditor, and advisory approval of named executive officer compensation. The filing presents vote tallies (For, Against, Abstain, Broker Non-Votes) for each proposal, which is the core content of shareholder vote results disclosures.
View raw filing on EDGAR →The filing discloses a common stock purchase agreement with White Lion Capital LLC for up to $15.0 million in equity financing, with actual purchases of 7,500 shares totaling $15,650 completed as of May 22, 2026. This represents a dilutive issuance of common stock under a committed purchase arrangement, which is material to investors assessing the registrant's capital structure and ownership dilution.
View raw filing on EDGAR →Editas disclosed positive preclinical data for EDIT-401 demonstrating robust reductions in LDL-C, Lp(a), and ApoB in non-human primates, along with plans to initiate a first-in-human clinical trial in 2026 and FDA pre-IND feedback. This announcement represents material progress on a lead pipeline candidate for a gene-editing biotech company where clinical advancement is a key value driver.
View raw filing on EDGAR →ARES Strategic Income Fund entered into an amendment and restatement of its senior secured credit facility with JPMorgan Chase Bank on May 21, 2026, materially increasing the aggregate commitment from $3.25 billion to $4.1 billion (with an accordion feature to $6.15 billion), extending maturity dates by approximately one year, and modifying key terms including interest rate mechanics and covenant restrictions.
View raw filing on EDGAR →Ares Capital amended and restated its senior secured credit facility on May 21, 2026, increasing total commitments from $5.312 billion to $5.481 billion, extending maturity to May 21, 2031, and modifying covenant restrictions and interest rate terms. This material refinancing represents a significant modification to the Company's capital structure and financing arrangements.
View raw filing on EDGAR →The Company closed a $68 million Series B Revolving Equipment Notes Facility, generating $64.3 million in net cash proceeds. The facility is secured by aircraft collateral and includes cross-default provisions tied to Delta's credit agreement, representing a material financing transaction affecting the Company's liquidity and debt structure.
View raw filing on EDGAR →This Item 5.07 disclosure reports the results of Passage Bio's 2026 Annual Meeting of Stockholders held on May 19, 2026, including voting outcomes on four proposals: election of two Class III directors (Athena Countouriotis, M.D. and Sandip Kapadia), ratification of KPMG LLP as independent auditor, advisory approval of named executive officer compensation, and advisory vote on compensation vote frequency. The filing presents vote tallies (For, Against, Abstaining, Broker Non-Votes) for each proposal, making this a classic shareholder_vote_results disclosure.
View raw filing on EDGAR →The FDA has granted Outlook's appeal of a Complete Response Letter for its BLA for LYTENAVA™, concluding that substantial evidence of effectiveness has been established and directing the company to work on final labeling for resubmission in June 2026. This is a material regulatory milestone for a biopharmaceutical company's lead product candidate, but it does not fit neatly into the standard taxonomy categories (not an earnings release, not a departure/appointment, not M&A, not a restatement or going-concern issue). The favorable FDA determination materially advances the product toward approval and would significantly affect investor assessment of the company's prospects.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from Camping World's Annual Meeting of Stockholders held on May 21, 2026. The filing reports the outcomes of three proposals: election of three Class I directors (Mary J. George, K. Dillon Schickli, and Matthew D. Wagner), ratification of Deloitte & Touche LLP as independent auditor, and advisory approval of named executive officer compensation. All proposals passed with strong majorities, and the results are material to investors as they reflect governance decisions and shareholder approval of key corporate matters.
View raw filing on EDGAR →The filing discloses that Cypherpunk Technologies received a Nasdaq deficiency notice on March 4, 2026 for failing to maintain the minimum $1.00 bid price requirement for 30 consecutive business days, triggering delisting risk under Nasdaq Listing Rule 5550(a)(2). Although the company subsequently regained compliance by May 21, 2026, the disclosure of the initial deficiency notice and the cure period is a material delisting-risk event that would affect investor assessment of listing status and financial condition.
View raw filing on EDGAR →Editas suspended and terminated its prospectus supplement for an at-the-market (ATM) offering program with TD Cowen, effectively halting its ability to raise capital through this mechanism without filing a new prospectus. The company had previously raised $43.9 million through this program. While this is a material event affecting the company's financing flexibility, it does not fit neatly into the standard taxonomy—it is neither a dilutive issuance (which describes the sale itself) nor a delisting risk, but rather a suspension of an existing capital-raising program that would materially impact investor assessment of the company's liquidity and financing options.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of Verastem's 2026 annual meeting of stockholders held on May 21, 2026. The filing presents voting outcomes for five proposals: election of Class II directors (Michael Bailey, Brian Stuglik, Karin Tollefson), approval of the Amended 2021 Equity Incentive Plan, approval of the Amended 2018 Employee Stock Purchase Plan, ratification of Ernst & Young LLP as auditor, and a non-binding advisory vote on named executive officer compensation. All proposals passed with substantial majorities, making this a material disclosure of shareholder voting results.
View raw filing on EDGAR →This disclosure reports interim clinical and biomarker data from a Phase 1b extension study of GT-02287 for Parkinson's disease, including safety, tolerability, and efficacy endpoints (GluSph reduction of 81%, stable MDS-UPDRS scores, and perceived clinical benefits). While this is a material clinical development update that would affect investor assessment of the drug candidate's progress, it does not fit neatly into the predefined taxonomy—it is neither an earnings release, M&A activity, executive change, nor a negative event like restatement or going concern. The disclosure is material because clinical trial progress is central to a biopharmaceutical company's value proposition.
View raw filing on EDGAR →Daniel J. Roller resigned from the Board of Directors effective immediately on May 21, 2026. The disclosure explicitly states this is a resignation under Item 5.02(b), which covers departures of directors and officers. The filing confirms no disagreement preceded the departure, but the loss of a board member is material to investors assessing governance and board composition.
View raw filing on EDGAR →This Item 5.07 discloses the final results of the 2026 Annual Meeting of Stockholders held on May 22, 2026, including voting outcomes for three proposals: election of six directors, advisory vote on named executive officer compensation, and ratification of Deloitte & Touche LLP as independent auditor. The detailed vote tallies (For, Against, Abstentions, Broker Non-Votes) for each proposal are the core disclosure, which is the defining characteristic of shareholder_vote_results.
View raw filing on EDGAR →This Item 5.07 disclosure reports the results of Gevo's 2026 Annual Meeting of Stockholders held on May 20, 2026, with detailed voting tallies for three proposals: election of three Class I directors (Barber, Bloom, Gruber), ratification of Deloitte & Touche LLP as independent auditor, and an advisory vote on named executive officer compensation. The filing directly matches the shareholder_vote_results event type and is material as it documents stockholder approval of board composition and auditor appointment.
View raw filing on EDGAR →Wendy Cassity, the Chief Legal Officer and Corporate Secretary of XPO, Inc., notified the company on May 20, 2026 of her intention to resign effective June 18, 2026. The departure of a named executive officer in a senior legal and governance role is material to investors' assessment of the company's leadership and operational continuity.
View raw filing on EDGAR →The filing discloses Item 5.07 results from Global Net Lease's May 21, 2026 annual meeting of stockholders, including voting outcomes for three proposals: election of eight directors, ratification of PricewaterhouseCoopers LLP as independent auditor, and advisory approval of named executive officer compensation. The detailed vote tallies (For, Against, Withheld, Abstentions, Non-Votes) for each proposal are the core disclosure, making this a shareholder vote results event material to investors assessing board composition and governance.
View raw filing on EDGAR →This Item 5.07 disclosure reports the results of Miller Industries' Annual Meeting of Shareholders held on May 22, 2026, including voting outcomes on three matters: election of seven directors, non-binding advisory vote on named executive officer compensation, and ratification of Elliot Davis, LLC as independent auditor. The detailed vote tallies (for, against, withheld, abstain, non-votes) for each matter are the core content of a shareholder vote results disclosure, which is material to investors assessing board composition and governance.
View raw filing on EDGAR →Cogent Communications entered into a definitive Purchase and Sale Agreement to sell 10 data center facilities for $225 million to an I Squared Capital affiliate, representing a material disposition of assets that will significantly affect the company's asset base and cash position.
View raw filing on EDGAR →Bentley Systems held its 2026 Annual Meeting of Stockholders on May 21, 2026, with final voting results disclosed for three proposals: election of eight directors, advisory vote on named executive officer compensation, and ratification of KPMG LLP as independent auditor.
View raw filing on EDGAR →NorthEast Community Bancorp held its annual meeting of stockholders on May 21, 2026, with shareholders voting on three matters: election of four directors (Lynette Bennett, Jose M. Collazo, John F. McKenzie, and Joel L. Morgenthau), approval of the 2026 Equity Incentive Plan, and ratification of S.R. Snodgrass, P.C. as independent auditor. All three proposals passed with substantial majorities.
View raw filing on EDGAR →The filing discloses the dismissal of MaloneBailey, LLP as the Company's independent registered public accounting firm effective immediately on May 26, 2026, and the concurrent appointment of RSM US LLP as the new auditor. This is a classic auditor change under Item 4.01. The disclosure explicitly states there were no disagreements, adverse opinions, or reportable events, which are standard representations in routine auditor transitions. The materiality is high because auditor changes are material to investors' assessment of financial reporting reliability.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of CPI Card Group's 2026 annual meeting of stockholders held on May 21, 2026. The filing presents voting tallies for three standard proposals: election of eight directors, ratification of KPMG LLP as independent auditor, and advisory approval of named executive officer compensation. All three proposals passed with substantial majorities, making this a routine but material shareholder vote results disclosure.
View raw filing on EDGAR →The filing discloses the net asset value (NAV) per share of Eagle Point Trinity Senior Secured Lending Company as of April 30, 2026 ($10.18). For a closed-end investment company or BDC, NAV disclosure is a standard periodic reporting requirement that would be material to investors assessing the fund's performance and valuation, though it does not fit neatly into the more specific event categories (earnings release, impairment, going concern, etc.). This is classified as other_material because it is a substantive disclosure affecting investor assessment but lacks a dedicated taxonomy category.
View raw filing on EDGAR →The filing explicitly discloses that Modine Manufacturing issued a press release on May 26, 2026 announcing "results of operations and financial condition for the fourth quarter and fiscal year ended March 31, 2026." The press release and earnings presentation are attached as exhibits (99.1 and 99.2), and executives Neil D. Brinker (President and CEO) and Michael B. Lucareli (CFO) will discuss these results on a conference call. This is a standard earnings release disclosure under Item 2.02.
View raw filing on EDGAR →This is Item 5.07 disclosing the final certified voting results from Jackson Financial Inc.'s Annual Meeting of Shareholders held on May 21, 2026. The filing reports results for three proposals: election of nine directors to the Board, ratification of KPMG LLP as independent auditor for fiscal year 2026, and non-binding advisory approval of executive compensation. All three proposals passed with substantial majorities, as evidenced by the vote tallies presented.
View raw filing on EDGAR →This Item 5.07 disclosure reports the results of Howmet Aerospace's 2026 annual shareholder meeting held on May 19, 2026, including voting outcomes on three proposals: election of nine directors, ratification of PricewaterhouseCoopers LLP as independent auditor, and an advisory vote on executive compensation. The filing provides detailed vote tallies (For, Against, Abstain, Broker Non-Votes) for each matter, which is the core content of shareholder_vote_results disclosures.
View raw filing on EDGAR →Starwood Property Trust closed a $600 million private offering of 6.125% senior notes due 2031 on May 26, 2026, under an indenture with The Bank of New York Mellon. The proceeds were used for refinancing existing debt and funding green/social projects, representing a material capital structure change.
View raw filing on EDGAR →Stockholders approved an amendment to the 2009 Equity Incentive Plan at the May 19, 2026 Annual Meeting, authorizing an additional 1,600,000 shares for equity compensation.
View raw filing on EDGAR →The company amended the Omnicell, Inc. 2009 Equity Incentive Plan to modify compensatory arrangements for officers and directors, affecting the equity compensation structure.
View raw filing on EDGAR →Editas Medicine entered into an underwriting agreement on May 26, 2026 to conduct a public offering of 55,555,556 shares of common stock at $2.25 per share, together with accompanying warrants, generating approximately $117.0 million in net proceeds. The offering, which will fund operations into H2 2028, represents a material registered public offering that will dilute existing shareholders, with the warrant component potentially generating an additional $192.5 million upon exercise.
View raw filing on EDGAR →The filing discloses an At The Market (ATM) Offering Agreement entered into on March 10, 2025, permitting Traws Pharma to offer and sell up to $3,128,399 of common stock shares through Citizens JMP Securities under an effective shelf registration statement. ATM offerings are unregistered equity issuances that are dilutive to existing shareholders and typically signal capital-raising activity at small- and mid-cap issuers; this disclosure is material to investor assessment of equity dilution and the company's liquidity position.
View raw filing on EDGAR →Trinseo PLC filed voluntary petitions under Chapter 11 of the Bankruptcy Code on May 26, 2026, in the U.S. Bankruptcy Court for the Southern District of Texas, and will operate as a debtor-in-possession. The filing includes a press release, Disclosure Statement for creditors voting on a reorganization plan, and Combined Notice of the Chapter 11 Cases, with cautionary language that existing equity holders are expected to have their equity interests cancelled and will receive no recovery.
View raw filing on EDGAR →This Item 5.07 discloses the final certified voting results from Illumina's May 21, 2026 annual meeting of stockholders, including results for three proposals: election of nine directors, ratification of Ernst & Young LLP as independent auditor, and advisory approval of named executive officer compensation. The Inspector of Election certified the results on May 22, 2026, with detailed vote tallies for each proposal and director nominee. This is a textbook shareholder_vote_results disclosure.
View raw filing on EDGAR →This Item 5.07 filing discloses the final results of First Northern Community Bancorp's Annual Meeting of Shareholders held on May 19, 2026, including voting outcomes on three proposals: election of eleven directors, advisory approval of named executive officer compensation, and ratification of Baker Tilly US LLP as independent auditor. The detailed vote tallies for each director and proposal are the core disclosure, making this a textbook shareholder_vote_results event that is material to investors assessing board composition and governance.
View raw filing on EDGAR →BlackRock Private Credit Fund disclosed an unregistered sale of 376,795.093 Institutional Class Shares for $8.9 million to feeder vehicles, exempt under Section 4(a)(2) and Regulation S, increasing share count and diluting existing shareholders' ownership interests.
View raw filing on EDGAR →This Item 5.07 disclosure reports the results of WTI Fund XI, Inc.'s annual shareholder meeting held on May 20, 2026, including voting outcomes on the election of five board members (Monica Lai, Arthur Spinner, Scott C. Taylor, David R. Wanek, and Maurice C. Werdegar) and ratification of Deloitte & Touche LLP as independent auditor. Both proposals passed with 71.08% of LLC Shares voting in favor, meeting the required plurality and majority thresholds respectively.
View raw filing on EDGAR →This Item 5.07 disclosure reports the results of the annual shareholder meeting held on May 20, 2026, where shareholders voted on the election of four board members (Roger V. Smith, Robert J. Hutter, Scott C. Taylor, and Maurice C. Werdegar) and ratification of Deloitte & Touche LLP as independent auditor. Both proposals passed with 87.82% of LLC Shares voting in favor. The disclosure directly matches the shareholder_vote_results event type and is material as it documents governance decisions affecting board composition and auditor selection.
View raw filing on EDGAR →This Item 5.07 disclosure reports the results of WTI Fund X's annual shareholder meeting held on May 20, 2026, including voting outcomes for the election of four board members (Spiro C. Lazarakis, William R. Miller, Georganne Perkins, and David R. Wanek) and ratification of Deloitte & Touche LLP as independent auditor. Both proposals passed with 73.28% of LLC membership shares voting in favor. This is a classic shareholder vote results disclosure required under Item 5.07.
View raw filing on EDGAR →The filing discloses a proposed business combination between TMTG and TAE Technologies, Inc., with the Interim CEO discussing the transaction in a media interview. The extensive disclosure of transaction details, forward-looking statements about merger timing and terms, and planned SEC filings (Form S-4, proxy statement/prospectus) are hallmarks of material M&A activity. This is a transformative transaction requiring shareholder approval and SEC registration.
View raw filing on EDGAR →The filing discloses financial results for the second quarter ended March 31, 2026, via a press release issued on May 21, 2026, and furnished as Exhibit 99.1. This is a standard earnings release disclosure under Item 2.02, which is material to investors as it provides periodic financial performance information.
View raw filing on EDGAR →Insulet disclosed a voluntary medical device correction affecting approximately 7 million Omnipod® Pods due to manufacturing issues (cannula tears), with expected costs up to $50 million in 2026. While the company states it does not anticipate disruption to shipments or guidance changes, the scale of the correction (7 million units), the financial impact ($50 million), and the reputational/regulatory implications of a second related correction within months constitute a material event. This does not fit neatly into existing categories (not a restatement, impairment, or litigation settlement), making "other_material" the most appropriate classification.
View raw filing on EDGAR →The filing discloses AutoZone's earnings for the fiscal quarter ended May 9, 2026 via a press release furnished as Exhibit 99.1. This is a standard quarterly earnings release under Item 2.02, which is material to investors as it provides financial results and operational performance for the period.
View raw filing on EDGAR →QCR Holdings held its Annual Meeting on May 21, 2026, with shareholders voting on three proposals: election of four Class III directors, a say-on-pay advisory vote on executive compensation, and ratification of RSM US LLP as independent auditor. The filing discloses the voting results for each matter.
View raw filing on EDGAR →Silexion announced a 1-for-10 reverse share split effective May 28, 2026, following shareholder approval on May 5, 2026. While reverse splits are routine capital structure adjustments, this disclosure is material because it affects the total mix of information available to investors regarding share ownership, voting power, and trading mechanics. The event does not fit the more specific categories (not a dilutive issuance, not a restatement, not an impairment), making "other_material" the appropriate classification.
View raw filing on EDGAR →The filing discloses that Calavo Growers and Mission Produce obtained antitrust clearance from Mexico's COFECE for the previously announced acquisition of Calavo by Mission Produce, with expected consummation on May 28, 2026. This represents a material milestone in a merger transaction—the removal of a significant closing condition—and directly impacts the registrant's control and ownership structure. The disclosure is explicitly about M&A activity completion.
View raw filing on EDGAR →Goldman Sachs Private Credit Corp. completed an unregistered sale of approximately $84.2 million in Class I and Class S shares to accredited investors and non-U.S. persons, exempt under Section 4(a)(2), Regulation D, and/or Regulation S.
View raw filing on EDGAR →The Company reported its Net Asset Value as of April 30, 2026 of $9.3 billion total ($24.66 per share across all classes) and fund leverage of 0.8x, providing material valuation and financial position metrics to investors.
View raw filing on EDGAR →